Key Developments: Agilent Technologies Inc (A)

A on New York Consolidated

53.05USD
22 Oct 2014
Price Change (% chg)

$-0.95 (-1.76%)
Prev Close
$54.00
Open
$53.77
Day's High
$53.86
Day's Low
$52.99
Volume
2,161,086
Avg. Vol
2,106,735
52-wk High
$61.22
52-wk Low
$49.80

Search Stocks

Latest Key Developments (Source: Significant Developments)

Agilent Technologies announces cash dividend of $0.132 per share
Thursday, 22 May 2014 08:00am EDT 

Agilent Technologies Inc:Declares cash dividend of $0.132 per share.Payable on July 23 to all shareholders of record as of the close of business on July 1.  Full Article

Agilent Technologies Inc gives Q3 2014 guidance; EPS guidance below analysts' estimates; reaffirms FY 2014 guidance
Wednesday, 14 May 2014 04:05pm EDT 

Agilent Technologies Inc:Expects Q3 2014 revenues to be in range of $1.74 bln to $1.76 bln.Expects Q3 2014 non-GAAP earnings to be in range of $0.72 to $0.74 per share (EPS).Expects FY 2014 revenue of $6.90 bln to $7.10 bln.Expects FY 2014 non-GAAP earnings of $2.96 to $3.16 per share.Q3 2014 revenue of $1.74 bln and EPS of $0.79 - Thomson Reuters I/B/E/S.FY 2014 revenue of $6.98 bln and EPS of $3.08 - Thomson Reuters I/B/E/S.  Full Article

Dako, Agilent Technologies Inc company, launches two ready-to-use antibodies for cancer diagnosis
Friday, 2 May 2014 09:10am EDT 

Agilent Technologies Inc:Dako, an Agilent Technologies company, launches addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to Dako portfolio of high-quality reagents, instruments and software.Anti-CK 8/18 is first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from major pathology provider.It is used by pathologists to stain CK 8/18 in tissue samples and thereby help classify tumors of unknown origin.Keratins are one of most potent epithelial differentiation and tumor markers in cancer diagnostics.Both Anti-CK 8/18 and Anti-TdT provide excellent specificity and sensitivity and have been reviewed and accepted by key pathology experts.Both antibodies provide optimal staining results enabled by the FLEX Ready-to-Use Dako solutions.  Full Article

Agilent Technologies Inc acquires electrothermal analysis technology from Gradient Design Automation
Wednesday, 30 Apr 2014 11:00am EDT 

Agilent Technologies Inc:Announces acquisition of electrothermal analysis technology from Gradient Design Automation, the maker of HeatWave electrothermal analysis software.Electrothermal analysis technology allows designers to identify and correct thermal problems during integrated circuit development.  Full Article

CORRECTION OFFICIAL - Agilent Technologies Inc announces cash dividend
Tuesday, 1 Apr 2014 01:36pm EDT 

CORRECTED TO READ - "quarterly dividend of $0.132 per share"... INSTEAD OF ... "quarterly dividend of $0.13 per share"... IN THE BODY.Agilent Technologies Inc:Declares quarterly dividend of $0.132 per share.Payable on April 23 to all shareholders of record as of the close of business on April 11.  Full Article

Genetic Technologies Ltd announces that Californian court denies motion to dismiss, brought by Agilent Technologies Inc
Tuesday, 11 Mar 2014 06:03pm EDT 

Genetic Technologies Ltd:Says that the United States District Court for Northern District of California has last week issued an order denying a motion brought by Agilent Technologies Inc, to dismiss the patent infringement law suit brought against it by GTG.Action was initially brought by GTG against Agilent in 2011, in the District Court of Colorado, but was then moved at request of Agilent to District Court in Northern District of California.Thereafter, both sides filed motions in support of their different legal perspectives.Most recently, Agilent moved to have GTG's complaint dismissed, arguing the relevant GTG patent covers natural phenomena or laws of nature that are not entitled to patent protection, and that court should therefore dismiss action.On March 9, the court issued order denying Agilent's motion to dismiss.  Full Article

Agilent Technologies Inc introduces Handheld FTIR Spectrometer
Monday, 3 Mar 2014 11:00am EST 

Agilent Technologies Inc:Introduces a mobile spectroscopy product that is ideal for on-site testing in a broad range of applications, including advanced materials, art, historical objects, geology, agriculture, composites, coatings and polymers.  Full Article

Agilent Technologies Inc and CambTEK to provide combined solution for liquid chromatography
Monday, 24 Feb 2014 11:00am EST 

Agilent Technologies Inc and CambTEK Ltd:Says agreement to co-market CambTEK's Rapid Extraction System (RES) automated sample preparation technology with an assortment of Agilent's liquid phase separation, life science and chemical analysis instruments and software.Used together, these laboratory solutions provide analytical researchers in the pharmaceutical, chemical and food industries with powerful tools to increase the speed and efficiency of laboratory workflows and maximize the quality of their results.  Full Article

Agilent Technologies Inc announces new study reinforces major advantages of Dako's HER2 IQFISH pharmDx in Breast Cancer Diagnostics
Friday, 14 Feb 2014 09:11am EST 

Agilent Technologies Inc:Says positive findings in an independent French multicenter study on the performance of Dako's HER2 IQFISH pharmDx.Says the Toulouse, France, breast cancer group led by Magali Lacroix-Triki has published a peer-reviewed publication in the Journal of Histopathology.Says that supports the use and performance of Dako's HER2 IQFISH pharmDx for HER2 gene amplification status assessment in breast cancer.Says Dako introduced the cutting-edge IQFISH hybridization buffer chemistry in 2012.Says the IQFISH buffer reduces test turnaround time from 17 hours to just 3.5 hours.Says more than 1.5 mln new cases of breast cancer are diagnosed each year worldwide.Says as an aid in the treatment decision, HER2 IQFISH pharmDx can quantitatively determine HER2 gene amplification in the tumor.Says the study concludes that the highly concordant results (99.3 pct) and assay robustness support IQFISH as a useful alternative to FISH, allowing reliable assessment of HER2 status.Says it also finds that using this method enables pathologists to report the results to the oncologist within a day, meaning patients can begin cancer treatment sooner than ever.  Full Article

Agilent Technologies Inc gives Q2 2014 guidance below analysts' estimates; lowers FY 2014 guidance
Thursday, 13 Feb 2014 04:05pm EST 

Agilent Technologies Inc:Expects Q2 2014 revenues to be in the range of $1.72 billion to $1.74 billion.Expects Q2 2014 non-GAAP earnings to be in the range of $0.71 to $0.73 per share.Expects fiscal 2014 revenue of $6.90 billion to $7.10 billion.Expects fiscal 2014 non-GAAP earnings of $2.96 to $3.16 per share (EPS).Q2 2014 revenues of $1.78 billion and EPS of $0.81 - Thomson Reuters I/B/E/S.FY 2014 revenue of $7.05 billion and EPS of $3.19 - Thomson Reuters I/B/E/S.  Full Article

Fitch Assigns Initial IDR of 'BBB' to Keysight Technologies; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, September 12 (Fitch) Fitch Ratings has assigned Keysight Technologies Inc. (Keysight) an initial long-term Issuer Default Rating (IDR) of 'BBB' in anticipation of Keysight's spin-off from parent, Agilent Technologies, Inc. (Agilent). The Rating Outlook is Stable. On Sept. 13, 2014, Agilent announced it planned to separate its Electronics Measurement (EM) segment from the Life Sciences, Diagnostics and Applied Markets (LDA

Search Stocks